Gland Pharma IPO price band at Rs 1,490-1,500, offer opens on Nov 9

Gland Pharma, which announced itsabout Rs 6,500 crore IPO, has set a price band of Rs 1,490-1,500 per share (face value of Rs one) and the issue will be open on November 9, an official said

IPO
Press Trust of India Hyderabad
2 min read Last Updated : Nov 04 2020 | 2:49 PM IST

Gland Pharma, which announced its

about Rs 6,500 crore Initial Public Offer (IPO), has set a price band of Rs 1,490-1,500 per share (face value of Rs one) and the issue will be open on November 9, a senior official of the city-based drug maker said on Wednesday.

Srinivas Sadhu, MD and CEO of Gland Pharma, said the company plans to raise up toRs 1,250 crore through issuance of fresh equity and allow its China-based promoter Fosun Pharma Industrial Pte Ltd and Gland Celsus Chemicals Pvt Ltd another shareholder to sell a part of their stake.

"The price band has been decided at Rs 1,490 to Rs 1,500.

At the top end of the price band the issue is Rs 6480 crore.

The primary issue size is Rs 1,250 crore.

The total secondary offer is about 22.5 per cent of the pre-issue capital with Fosun Group offering 12.5 per cent of the total pre-issue capital and the rest is coming from the other selling shareholders of 10 per cent," Sadhu told reporters in a press conference.

The total dilution is therefore 26.48 per cent at the top end of the price band, he added.

The anchor issue for institutional investors opens on November 6, while the issue will come on November 9 and the issue closes on November 11.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :IPOGland Pharma

First Published: Nov 04 2020 | 2:44 PM IST

Next Story